Proposed Topic (Most preferred): :
Enhancing Partnership with Patients and Community (Projects initiated to engage patients / carers / community to improve efficiency / quality of care)
Authors (including presenting author) :
Fok GW
Affiliation :
Our Lady of Maryknoll Hospital
Introduction :
Trials have given the support that high-intensity statin therapy may be more effective than low-intensity therapy in terms of secondary prevention of cardiovascular events. Compared with moderate-intensity statin therapy, high-intensity statin therapy demonstrated a higher reduction in atherosclerosis progression in patients with coronary artery disease. Despite these established benefits, statins still appeared to be used at suboptimal doses, even in the populations at the highest risk of cardiovascular events and mortality.
Objectives :
This study investigates the prevalence of secondary ASCVD in patients with statin therapy adhered to the 2018 AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults vs patients with non guideline-adhered statin therapy and evaluates the prevalence of patients with suboptimal statin therapy for secondary ASCVD prevention.
Methodology :
This is a retrospective and cross-sectional study that was conducted at a local hospital between November 2020 to July 2022. A total of 140 patients who had clinical ASCVDs and were taking statins were sampled for inclusion into this study. Patients were followed up for 16 months for investigation of occurrence of secondary ASCVD events.
Result & Outcome :
Three folds more patients (76.4%) were having non guideline-directed statin therapy than guideline-directed ones (23.6%) (P< 0.01, α=0.01). A total of 8 patients had secondary ASCVDs within the tracking period of 16 months. All of them belonged to the non guideline-directed group (P=0.2, α=0.05).Non guideline-directed statin therapies lead to a higher risk of developing secondary ASCVD. Therefore, it is suggested that guideline-directed statin therapies should be prescribed to have a better cardiovascular outcome. However, patient tolerance should also be considered when adjusting statin therapies to individual.
